Results 71 to 80 of about 18,542 (210)

Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy [PDF]

, 2015
OBJECTIVE: To determine the frequency of pharmacogenomic variants and concurrent medications that may alter the efficacy and tolerability of acetylcholinesterase inhibitors (AChEIs).
Boustani, Malaz A., Campbell, Noll L., Gao, Sujuan, Khan, Babar A., Li, Lang, Perkins, Anthony J., Skaar, Todd C.   +6 more
core   +2 more sources

Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia

Brain Sciences
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60. It is defined by motor and nonmotor symptoms including a spectrum of cognitive impairments known as Parkinson’s disease dementia (PDD ...
Emma D. Frost, Swanny X. Shi, Vishnu V. Byroju, Jamir Pitton Rissardo, Jack Donlon, Nicholas Vigilante, Briana P. Murray, Ian M. Walker, Andrew McGarry, Thomas N. Ferraro, Khalid A. Hanafy, Valentina Echeverria, Ludmil Mitrev, Mitchel A. Kling, Balaji Krishnaiah, David B. Lovejoy, Shafiqur Rahman, Trevor W. Stone, Maju Mathew Koola   +18 more
doaj   +1 more source

Cognitive dysfunction and dementia in Parkinson's disease [PDF]

, 2004
Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder mainly characterized by degeneration of dopaminergic neurons in the substantia nigra and the ventral tegmental area, in combination with a varying loss of central noradrenergic ...
Bosboom, JL, Stoffers, D., Wolters, E.C.M.J.   +2 more
core   +1 more source

Synthesis of p‐Coumarates With Potential Anti‐Alzheimer's Action: Enzyme Inhibition and In Silico Studies

Chemistry &Biodiversity, Volume 23, Issue 4, April 2026.
ABSTRACT Alzheimer's disease (AD) is a fatal neurodegenerative disorder that affects cognition, memory, and behavior. Such a disease is considered the most common cause of dementia and affects a large portion of the elderly population worldwide. Currently, cholinesterase inhibitors are used to reduce the symptoms and rate of progression of this disease.
Susiany Pereira Lopes, Jeremias Justo Emídio, Allana Brunna Sucupira Duarte, Ilkay Erdogan Orhan, Fatma Sezer Senol Deniz, Ramin Ekhteiari Salmas, Damião Pergentino de Sousa   +6 more
wiley   +1 more source

Regulation of prefrontal glutamate by the endogenous neuromodulator kynurenic acid as measured by rapid electrochemistry: relevance to schizophrenia [PDF]

, 2010
Schizophrenia is one of the most debilitating neuropsychiatric disorders, with a prevalence of approximately 1% worldwide. Symptoms include impairing deficits in cognitive processes (e.g., working memory, attention, and cognitive flexibility) which are ...
Campbell, Andrew
core  

Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation [PDF]

, 2017
Background: Alzheimer pathogenesis has been associated with a network of processes working simultaneously and synergistically. Over time, much interest has been focused on cholinergic transmission and its mutual interconnections with other active players
Abu, Izuddin F., Andrisano, Vincenza, Bartolini, Manuela, Bergamini, Christian, Blockley, Alix, Bottegoni, Giovanni, Caporaso, Roberta, Cavalli, Andrea, Gotti, Cecilia, Mellor, Ian R., Minarini, Anna, Rosini, Michela, Simoni, Elena   +12 more
core   +2 more sources

Binding Mode Analysis of Antifouling Compounds Targeting Tyrosinase and Acetylcholinesterase by Saturation Transfer Difference NMR Spectroscopy

ChemBioChem, Volume 27, Issue 8, April 2026.
Mussels are key macrofoulers targeted by antifouling (AF) strategies, yet few molecular targets have been explored to guide the development of new ecofriendly agents. Here, saturation transfer difference‐nuclear magnetic resonance (STD‐NMR) is used to investigate the interactions between AF compounds and settlement‐related enzymes, namely, tyrosinase ...
Ana Sara Gomes, Mariana Andrade, Diana I. S. P. Resende, Sara M. Cravo, Emília Sousa, Marta Correia‐da‐Silva   +5 more
wiley   +1 more source

Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study

Neuropsychiatric Disease and Treatment, 2012
Zhenxin Zhang,1 Lu Yu,2 Maren Gaudig,3 Barbara Schäuble,4 Ute Richarz51Department of Neurology of Peking Union Medical College Hospital, 2Xi’an Janssen Pharmaceutical Ltd, Beijing, China; 3Health Economics and Reimbursement, Janssen ...
Zhang Z, Yu L, Gaudig M, Schäuble B, Richarz U   +4 more
doaj  

Potential therapeutic use of the ketogenic diet in autism spectrum disorders. [PDF]

, 2014
The ketogenic diet (KGD) has been recognized as an effective treatment for individuals with glucose transporter 1 (GLUT1) and pyruvate dehydrogenase (PDH) deficiencies as well as with epilepsy.
Dueñas, Nadia, Giulivi, Cecilia, Napoli, Eleonora   +2 more
core   +1 more source

Sparassis crispa and a Bioactive Compound Therein, Ergosterol, Were Effective in Preventing Acetylcholinesterase Inhibition In Vitro and In Vivo

Food Science &Nutrition, Volume 14, Issue 4, April 2026.
Sparassis crispa extract exhibited acetylcholinesterase inhibitory and antioxidant activities, and ergosterol was identified as a major bioactive sterol. In a TMT‐induced mouse model, both the extract and ergosterol improved spatial working memory and learning retention while reducing brain AChE activity and lipid peroxidation.
Chan Kyu Park, Gyumin Kang, Soo Jung Choi, Yoon Seo Lee, Eui‐Cheol Shin, Hyo In Kim, Jinbong Park, Nam Su Oh, Hyung Taek Cho, Tae Gyun Kim, Jeong Hoon Pan, Dong‐Hoon Shin, Young‐Jun Kim, Jae Kyeom Kim   +13 more
wiley   +1 more source